Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Cathepsin B is a cysteine protease that is primarily found in the lysosomes of normal cells, but it is secreted or associated with the plasma membrane of many transformed cells. It is found in all animals and other organisms, and performs a key role in cellular protein turnover. The cathepsin family includes serine proteases, aspartic proteases, and cysteine proteases. The aspartyl protease class is composed of cathepsins D and E. The cysteine protease class comprises of cathepsins B, L, H, K, S, and O. Currently, there are no approved cathepsin inhibitors in the market, however research is underway for the development of novel cathepsin inhibitors for treatment of various conditions such as cancer, traumatic brain injury, Ebola infection, and others.

Anti-cathepsin B is also used in screening kits for diagnostic purposes. Antibodies of cathepsin B are used that recognizes an epitope on the heavy chain of mature Cathepsin B and therefore detects both mature and pro Cathepsin B. The anti-cathepsin B antibodies are used for ELISA, western blotting, flow cytometry and other screening purposes. It can be used to screen diseases like demyelination, emphysema, rheumatoid arthritis, and neoplastic infiltration.

Anti-cathepsin B Market - Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic has significantly augmented demand of anti-cathepsin B market. The spread of coronavirus is positively impacted the anti-cathepsin B market as the antibodies are expected to potential cure for COVID-19. For instance, according to data published in the Journal of Clinical Medicine Research on 5th May 2020, acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin II receptor in different tissues of the body, especially in the mouth cavity and the tongue and the skin. Therefore, it needs the serine protease, transmembrane serine protease 2 (TMPRSS2) for cell entry. Cathepsin L/B (CTSL/CTSB) plays an important role in a second pathway, the endosomal pathway. Hence, anti-cathepsin B treatment may provide potential solutions for coronavirus treatment.

The anti-cathepsin B market is estimated to be valued at US$ 166.52 million in 2020 and is expected to exhibit a CAGR of 2.8 % during the forecast period (2020-2027).

Figure 1: Anti-cathepsin B Market Share (%) Analysis, By Type, 2020

Anti-Cathepsin B  | Coherent Market Insights

The Increasing Prevalence of Diseases Treated With Anti-Cathepsin B, and Research and Development Activities Are Expected To Drive Growth of the Anti-Cathepsin B Market

Anti-cathepsin B is expected to be useful for treating other conditions such as cancer, traumatic brain injury, Ebola infection, fertility problems, and others. Therefore, the increasing prevalence of such diseases is expected to boost the anti-cathepsin B market growth over the forecast period. For instance, according to the GLOBOCAN 2018 database, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. As per the same source, one in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease.

Furthermore, the anti-cathepsin B market is expected to witness significant growth in the near future owing to the increasing research and development activities. For instance, the report titled “Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate” published in Frontiers Neurology Journal in September 2015, showed supporting evidence for cathepsin B, a cysteine protease, as a potentially important drug target for traumatic brain injury (TBI). Cathepsin B expression is greatly up-regulated in TBI animal models, as well as in trauma patients.

Chemical inhibitors of cathepsin B are effective in improving deficits in TBI and related injuries including ischemia, cerebral bleeding, cerebral aneurysm, edema, pain, infection, rheumatoid arthritis, epilepsy, Huntington’s disease, multiple sclerosis, and Alzheimer’s disease. The inhibitor E64d is unique among cathepsin B inhibitors and is the only compound to have demonstrated oral efficacy in a TBI model and prior safe use in human and is an effective tool compound for preclinical testing and clinical compound development.

request-sample

Anti-cathepsin B Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 166.52 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 2.8% 2027 Value Projection: US$ 208.19 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel and rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Primary Antibodies, Proteins and Peptides, Lysates.
  • By Application: Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, Others.
  • By Technique: Immunohistochemistry, Immunofluorescence, Western Blotting, ELISA, Flow Cytometry, Others.
  • By End User: Pharmaceutical Companies, Academic and Research Institutes.
Companies covered:

Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc. and Abcam Plc.

Growth Drivers:
  • The increasing prevalence of disorders treated with anti-cathepsin B
  • The increasing number of research and developments activities

Anti-cathepsin B Market – Regional Analysis

The North America anti-cathepsin B market is expected to hold a dominant position in the global cathepsin inhibitors market owing to the high prevalence of conditions such as cancer and traumatic brain injury which will increase demand for novel treatment approaches such as anti-cathepsin B in this region. For instance, according to data published by the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer will be diagnosed in the U.S. and around 609,640 people will die from the disease.

Furthermore, a wide range of anti-cathepsin B products offered by key players is expected to accelerate the growth of the anti-cathepsin B market in the near future. For instance, Merck KGaA a Germany-based pharmaceutical, chemical and life sciences products company offers various anti-cathepsin products under the Calbiochem brand. The Cathepsin B Inhibitor II controls the biological activity of Cathepsin B. This small molecule/inhibitor is primarily used for Protease Inhibitors Techniques. The company also offers diagnostic products such as Cathepsin B Inhibitor Screening Kit which is a simple assay for screening potential inhibitors of CTSB (cathepsin B).

Figure 2: Anti-cathepsin B Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Anti-Cathepsin B  | Coherent Market Insights

Anti-cathepsin B Market - Competitive Landscape

Key players operating in the anti-cathepsin B market are Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc. and Abcam Plc

Anti-Cathespin B antibodies are majorly used for treatment of disease conditions such cancer, traumatic brain injury, Ebola infection, fertility problems, and are currently under research for treatment of SARS-CoV-2. Cathepsins play an important role in protein degradation and processing. Aberrant cathepsin B or L is closely associated with many diseases such as cancer, osteoporosis and autoimmune disorders. Therefore, development of potent and selective cathepsin B and L inhibitors has generated much attention in recent years. Although, several classes of cathepsin inhibitors are presently available, there are still some problems to solve such as a broad-spectrum inhibition to protease, especially cysteine proteases, which lead to unpredictable side effects in clinical trials.

Anti-Cathepsin B antibodies are available from several suppliers. In humans, this protein is encoded by the gene CTSB. The protein may also be known as APPS, CPSB, RECEUP, APP secretase, and amyloid precursor protein secretase. These anti-Cathepsin B antibodies are used for ELISA, western blotting, flow cytometry and other screening purposes.

Market Dynamics

The increasing research and development of anti-cathepsin B antibodies is expected to contribute to the anti-cathespin B market growth over the forecast period. For instance, according to the Springer Nature Journal’s report of July 2017, the effect of cathepsin B inhibitor, E-64, on developmental competency and cryo-survival of pre-implantation ovine IVF derived embryos was assessed. During the test, 1.0 μM of E-64 (Cathepsin B inhibitor) was added during day 3 to 8 of development of blastocyst in IVF derived embryos. And the results showed that the supplementation of IVC media with 1 μM E-64, an exogenous inhibitor of Cathepsins, improves quality and quantity of blastocyst formation. And hence, support the in vitro ovine embryos survival.

Furthermore, there are many developments in research of anti-cathepsin B antibodies. Many researchers are working on finding a cure with the help of anti-cathepsin B antibodies for diseases such as Alzheimer’s disease, rheumatism arthritis, tumor invasion and metastasis, inflammatory airway disease, chronic obstructive pulmonary disease, osteoarthritis, pneumocystis carinii, acute pancreatitis, and bone and joint disorders.

Key features of the study:

  • This report provides in-depth analysis of the global anti-cathespin B market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global anti-cathespin B market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study are Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc. and Abcam Plc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global anti-cathespin B market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for anti-cathespin B market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Anti-Cathespin B Market, By Type:
    • Primary Antibodies
    • Proteins and Peptides
    • Lysates
  • Global Anti-Cathespin B Market, By Research Application:
    • Cancer
    • Traumatic Brain Injury
    • Ebola Infection
    • Fertility Treatment
    • Others
  • Global Anti-Cathespin B Market, By Technique:
    • Immunohistochemistry
    • Immunofluorescence
    • Western Blotting
    • ELISA
    • Flow Cytometry
    • Others
  • Global Anti-Cathespin B Market, By End User:
    • Pharmaceutical Companies
    • Academic and Research Institutes
  • Global Anti-Cathespin B Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Type:
        • Primary Antibodies
        • Proteins and Peptides
        • Lysates
      • By Research Application:
        • Cancer
        • Traumatic Brain Injury
        • Ebola Infection
        • Fertility Treatment
        • Others
      • By Technique:
        • Immunohistochemistry
        • Immunofluorescence
        • Western Blotting
        • ELISA
        • Flow Cytometry
        • Others
      • By End User:
        • Pharmaceutical Companies
        • Academic and Research Institutes
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Type:
        • Primary Antibodies
        • Screening Kits
        • Proteins and Peptides
        • Lysates
      • By Research Application:
        • Cancer
        • Traumatic Brain Injury
        • Ebola Infection
        • Fertility Treatment
        • Others
      • By Technique:
        • Immunohistochemistry
        • Immunofluorescence
        • Western Blotting
        • ELISA
        • Flow Cytometry
        • Others
      • By End User:
        • Pharmaceutical Companies
        • Academic and Research Institutes
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Type:
        • Primary Antibodies
        • Screening Kits
        • Proteins and Peptides
        • Lysates
      • By Research Application:
        • Cancer
        • Traumatic Brain Injury
        • Ebola Infection
        • Fertility Treatment
        • Others
      • By Technique:
        • Immunohistochemistry
        • Immunofluorescence
        • Western Blotting
        • ELISA
        • Flow Cytometry
        • Others
      • By End User:
        • Pharmaceutical Companies
        • Academic and Research Institutes
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Type:
        • Primary Antibodies
        • Screening Kits
        • Proteins and Peptides
        • Lysates
      • By Research Application:
        • Cancer
        • Traumatic Brain Injury
        • Ebola Infection
        • Fertility Treatment
        • Others
      • By Technique:
        • Immunohistochemistry
        • Immunofluorescence
        • Western Blotting
        • ELISA
        • Flow Cytometry
        • Others
      • By End User:
        • Pharmaceutical Companies
        • Academic and Research Institutes
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Type:
        • Primary Antibodies
        • Screening Kits
        • Proteins and Peptides
        • Lysates
      • By Research Application:
        • Cancer
        • Traumatic Brain Injury
        • Ebola Infection
        • Fertility Treatment
        • Others
      • By Technique:
        • Immunohistochemistry
        • Immunofluorescence
        • Western Blotting
        • ELISA
        • Flow Cytometry
        • Others
      • By End User:
        • Pharmaceutical Companies
        • Academic and Research Institutes
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Type:
        • Primary Antibodies
        • Screening Kits
        • Proteins and Peptides
        • Lysates
      • By Research Application:
        • Cancer
        • Traumatic Brain Injury
        • Ebola Infection
        • Fertility Treatment
        • Others
      • By Technique:
        • Immunohistochemistry
        • Immunofluorescence
        • Western Blotting
        • ELISA
        • Flow Cytometry
        • Others
      • By End User:
        • Pharmaceutical Companies
        • Academic and Research Institutes
  • Company Profiles
    • Merck KGaA*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bio-Techne
    • BioVision Inc.
    • Santa Cruz Biotechnology, Inc.
    • MedChemExpress
    • BioCat GmbH
    • ApexBio Technology
    • Cayman Chemical
    • Selleck Chemicals
    • BOC Sciences
    • AG Scientific
    • Virobay Inc.
    • Abcam Plc

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Research Area
      • Market Snippet, By Application
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Regulatory Scenario
    • Reimbursement Scenario
    • New Product Launches/Approvals
    • Mergers & Acquisitions
    • Porter’s Analysis
    • PEST Analysis
  4. Global Anti-Cathepsin B Market, COVID-19 Impact Analysis
    • Pre-COVID-19 Market Scenario
    • Post COVID-19 Market Scenario
    • Strategies
  5. Global Anti-Cathepsin B Market, By Product Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Primary Antibodies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Proteins and Peptides
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Lysates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Anti-Cathepsin B Market, By Research Area, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Traumatic Brain Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Ebola Infection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Fertility Treatment
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Anti-Cathepsin B Market, By Application, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Immunohistochemistry
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Immunofluorescence
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Western Blotting
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • ELISA
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Flow Cytometry
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Anti-Cathepsin B Market, By End User, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Pharmaceutical Companies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Academic and Research Institutes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  9. Global Anti-Cathepsin B Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Research Area, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Research Area, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Research Area, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Research Area, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Research Area, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Research Area, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  10. Competitive Landscape
    • Company Profiles
      • Merck KGaA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bio-Techne
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • BioVision Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Santa Cruz Biotechnology, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • MedChemExpress
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • BioCat GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • ApexBio Technology
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Cayman Chemical
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Selleck Chemicals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • BOC Sciences
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AG Scientific
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Virobay Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Abcam Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 43 market data tables and 39 figures on "Global Anti-Cathepsin B Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the anti-cathepsin B market is 2.8 % during the forecast period (2020-2027).
The value of anti-cathepsin B market is estimated to be US$ 166.52 million in 2020.
The prominent players in the global anti-cathepsin B market are Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, Abcam Plc, and AG Scientific.
The anti-cathepsin B market is expected to be valued at US$ 208.19 million in 2027.
North America is the major region in the anti-cathepsin B market.
The increasing prevalence of diseases treated with anti-cathepsin B, and the increasing number of research and development activities are expected to drive growth of the anti-cathepsin B market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner